No Data
Sunho Biologics' Unit Enters Subscription Letters
Shenghe Biotech-B (02898) associated with the proposed subscription fund.
Shenghe Biotech-B (02898) issued an announcement on the Smart Finance app that on June 28, 2024, its indirect wholly-owned subsidiary Sunho HK (as a subscriber) entered into a subscription letter. Sunho HK agrees to subscribe to the funds (North Rock, Prudent Wealth, and Vanguard) according to the terms of the subscription letter. In order to improve fund efficiency and increase fund operating returns, the group will reasonably use its surplus cash to subscribe to these funds for financial management purposes to earn additional income without affecting normal operations.
Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut
Sunho Biologics Shares Rise 7% in Hong Kong Debut
IPO Announcement | Shenghe Bio-B (02898) was subscribed 10.08 times in public sale and listed on May 24
The company sold 34.1518 million shares globally, with the Hong Kong public offering accounting for 10% and the international offering accounting for 90%. The final sale price was HK$13.5 per share, with a net raise of approximately HK$391.6 million from the global offering
Sunho Biologics Files Prospectus for IPO
No Data
